Convenience, satisfaction, health-related quality of life of once-weekly 70 mg/m
Aged
Aged, 80 and over
Antineoplastic Agents
/ administration & dosage
Drug Administration Schedule
Humans
Kaplan-Meier Estimate
Middle Aged
Multiple Myeloma
/ diagnosis
Oligopeptides
/ administration & dosage
Patient Reported Outcome Measures
Patient Satisfaction
Quality of Life
Surveys and Questionnaires
Journal
Leukemia
ISSN: 1476-5551
Titre abrégé: Leukemia
Pays: England
ID NLM: 8704895
Informations de publication
Date de publication:
12 2019
12 2019
Historique:
received:
30
11
2018
accepted:
20
03
2019
revised:
14
03
2019
pubmed:
17
5
2019
medline:
27
5
2020
entrez:
17
5
2019
Statut:
ppublish
Résumé
We compared patient-reported outcomes (PROs) with once-weekly carfilzomib 70 mg/m
Identifiants
pubmed: 31092895
doi: 10.1038/s41375-019-0480-2
pii: 10.1038/s41375-019-0480-2
doi:
Substances chimiques
Antineoplastic Agents
0
Oligopeptides
0
carfilzomib
72X6E3J5AR
Banques de données
ClinicalTrials.gov
['NCT02412878']
Types de publication
Clinical Trial, Phase III
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
2934-2946Références
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.
doi: 10.1002/ijc.29210
Noone AM, Howlader N, Krapcho M, Miller D, Brest A, Yu M et al. SEER Cancer Statistics Review, 1975-2015, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2015/ based on November 2017 SEER data submission, posted to the SEER web site, April 2018. Accessed 8 June 2018.
Stewart AK, Dimopoulos MA, Masszi T, Špička I, Oriol A, Hájek R, et al. Health-related quality of life results from the open-label, randomized, phase III ASPIRE trial evaluating carfilzomib, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in patients with relapsed multiple myeloma. J Clin Oncol. 2016;34:3921–30.
pubmed: 27601539
pmcid: 5791840
Leleu X, Kyriakou C, Vande Broek I, Murphy P, Bacon P, Lewis P, et al. Prospective longitudinal study on quality of life in relapsed/refractory multiple myeloma patients receiving second- or third-line lenalidomide or bortezomib treatment. Blood Cancer J. 2017;7:e543.
pubmed: 28304402
pmcid: 5380904
Mortensen GL, Salomo M. Quality of life in patients with multiple myeloma: a qualitative study. J Cancer Sci Ther. 2016;8:289–93.
Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28:1122–8.
pubmed: 24157580
Turesson I, Bjorkholm M, Blimark CH, Kristinsson S, Velez R, Landgren O. Rapidly changing myeloma epidemiology in the general population: increased incidence, older patients, and longer survival. Eur J Haematol. 2018; https://doi.org/10.1111/ejh.13083
Thorsteinsdottir S, Dickman PW, Landgren O, Blimark C, Hultcrantz M, Turesson I et al. Dramatically improved survival in multiple myeloma patients in the recent decade: results from a Swedish population-based study. Haematologica 2018; https://doi.org/10.3324/haematol.2017.183475
pubmed: 29567776
pmcid: 6119139
Sparano F, Cavo M, Niscola P, Caravita T, Efficace F. Patient-reported outcomes in relapsed/refractory multiple myeloma: a systematic review. Support Care Cancer. 2018;26:2075–2090.
pubmed: 29560502
Sonneveld P, Verelst SG, Lewis P, Gray-Schopfer V, Hutchings A, Nixon A, et al. Review of health-related quality of life data in multiple myeloma patients treated with novel agents. Leukemia. 2013;27:1959–1969.
pubmed: 23783393
pmcid: 3806249
Nielsen LK, Jarden M, Andersen CL, Frederiksen H, Abildgaard N. A systematic review of health-related quality of life in longitudinal studies of myeloma patients. Eur J Haematol. 2017;99:3–17.
pubmed: 28322018
KYPROLIS® (carfilzomib) [prescribing information]: South San Francisco, CA: Onyx Pharmaceuticals, Inc.; 2018.
National Comprehensive Cancer Network (NCCN) 2018 guidelines. http://www.nccn.org/ . Accessed October 30, 2018.
Bringhen S, Larocca A, Rossi D, Cavalli M, Genuardi M, Ria R, et al. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood. 2010;116:4745–53.
pubmed: 20807892
Reeder CB, Reece DE, Kukreti V, Chen C, Trudel S, Laumann K, et al. Once-versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma. Blood. 2010;115:3416–7.
pubmed: 20413666
Barrett-Lee P, Bloomfield D, Dougherty L, Harries M, Laing R, Patel H, et al. An audit to determine the time taken to administer intravenous bisphosphonate infusions in patients diagnosed with metastatic breast cancer to bone in a hospital setting. Curr Med Res Opin. 2007;23:1575–82.
pubmed: 17559749
Oglesby A, Sherif B, Odom D, Leahy M, Qian Y. Time and costs associated with preparing and administering zoledronic acid in patients with breast or prostate cancer and metastatic bone disease. Commun Oncol. 2009;6:494–502.
Schwartzberg LS, Stepanski EJ, Walker MS, Mathias S, Houts AC, Fortner BV. Implications of IV monoclonal antibody infusion reaction for the patient, caregiver, and practice: results of a multicenter study. Support Care Cancer. 2009;17:91–98.
pubmed: 18592276
Xie F, Hophins RB, Burke N, Habib M, Angelis CD, Pasetka M, et al. Time and labor costs associated with administration of intravenous bisphosphonates for breast or prostate cancer patients with metastatic bone disease: a time and motion study. Hosp Pract. 2014;42:38–45.
Richhariya A, Qian Y, Zhao Y, Chung K. Time associated with intravenous zoledronic acid administration in patients with breast or prostate cancer and bone metastasis. Cancer Manag Res. 2012;4:55–60.
pubmed: 22427731
pmcid: 3304336
Fortner B, Viale PH. Health economic analysis of the burden of infusion reactions on patients, caregivers, and provider. Oncology. 2009;23:31–36.
pubmed: 19385165
Chadda S, Larkin M, Jones C, Sykes D, Barber B, Zhao Z, et al. The impact of infusion reactions associated with monoclonal antibodies in metastatic colorectal cancer: a European perspective. J Oncol Pharm Pract. 2013;19:38–47.
pubmed: 22735081
Moreau P, Mateos M-V, Berenson JR, Weisel K, Lazzaro A, Song K, et al. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. Lancet Oncol. 2018;19:953–64.
pubmed: 29866475
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in onocology. J Natl Cancer Inst. 1993;85:365–76.
Stead ML, Brown JM, Velikova G, Kaasa S, Wisløff F, Child JA, et al. Development of an EORTC questionnaire module to be used in health-related quality-of-life assessment for patients with multiple myeloma. European Organization for Research and Treatment of Cancer Study Group on Quality of Life. Br J Haematol. 1999;104:605–11.
pubmed: 10086801
Cocks K, Cohen D, Wisløff F, Sezer O, Lee S, Hippe E, et al. An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma. Eur J Cancer. 2007;43:1670–8.
pubmed: 17574838
Devlin NJ, Shah KK, Feng Y, Mulhern B, Van Hout B. Valuing health-related quality of life: an EQ-5D-5L value set for England. Health Econ. 2018;27:7–22.
pubmed: 28833869
Wisløff F, Eika S, Hippe E, Holmberg E, Kaasa S, Palva I, et al. Measurement of health-related quality of life in multiple myeloma. Nordic Myeloma Study Group. Br J Haematol. 1996;92:604–13.
pubmed: 8616024
Leleu X, Petrucci MT, Welslau M, Broek IV, Murphy PT, Bottomley A, et al. Psychometric performance of the EORTC Quality-of-life core questionnaire (QLQ-C30) and QLQ-multiple myeloma (QLQ-MY20) in relapsed/refractory multiple myeloma (RRMM). Blood 2013;122:1721.
Osborne TR, Ramsenthaler C, de Wolf-Linder S, Schey SA, Siegert RJ, Edmonds PM, et al. Understanding what matters most to people with multiple myeloma: a qualitative study of views on quality of life. BMC Cancer. 2014;14:496.
pubmed: 25005145
pmcid: 4227056
Patrick DL, Burke LB, Powers JH, Scott JA, Rock EP, Dawisha S, et al. Patient-reported outcomes to support medical product labeling claims: FDA perspective. Value Health. 2007;10:S125–37.
pubmed: 17995471
Cocks K, King MT, Velikova G, Martyn St-James M, Fayers PM, Brown JM. Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. J Clin Oncol. 2011;29:89–96.
pubmed: 21098316
Delforge M, Dhawan R, Robinson D Jr, Meunier J, Regnault A, Esseltine DL, et al. Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP vs. MP: results from the VISTA trial. Eur J Haematol. 2012;89:16–27.
pubmed: 22469559
Wyrwich KW, Tierney WM, Wolinsky FD. Further evidence supporting an SEM-based criterion for identifying meaningful intra-individual changes in health-related quality of life. J Clin Epidemiol. 1999;52:861–73.
pubmed: 10529027
McClure NS, Sayah FA, Xie F, Luo N, Johnson JA. Instrument-defined estimates of the minimally important difference for EQ-5D-5L index scores. Value Health. 2017;20:644–50.
pubmed: 28408007
Pickard AS, Neary MP, Cella D. Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes. 2007;5:70.
pubmed: 18154669
pmcid: 2248572
McLeod LD, Coon CD, Martin SA, Fehnel SE, Hays RD. Interpreting patient-reported outcome results: US FDA guidance and emerging methods. Expert Rev Pharm Outcomes Res. 2011;11:163–9.
Cocks K, Buchanan J. Defining responders on the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (30-Item core module) (QLQ-C30) subscales. Qual Life Res. 2015;24:125.
Liang K-Y, Zeger SL. Longitudinal data analysis of continuous and discrete responses for pre-post designs. Sankyā. 2000;62:134–48.
Vonesh EF, Greene T, Schluchter MD. Shared parameter models for the joint analysis of longitudinal data and event times. Stat Med. 2006;25:143–63.
pubmed: 16025541
Fairclough DL. Design and analysis of quality of life studies in clinical trials, 3rd edn. Boca Raton, FL: CRC Press; 2010.
Nunnally J, Bernstein I. Psychometric theory. Mcgraw-Hill: New York, NY, 1994.
Dimopoulos MA, Delforge M, Hájek R, Kropff M, Petrucci MT, Lewis P, et al. Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial. Haematologica. 2013;98:784–8.
pubmed: 23242595
pmcid: 3640125
Atherton PJ, Watkins-Bruner DW, Gotay C, Moinpour CM, Satele DV, Winter KA, et al. The complementary nature of patient-reported outcomes (PROs) and adverse event reporting in cooperative group oncology clinical trial: a pooled analysis (NCCTG N0591). J Pain Symptom Manage. 2015;50:470–9.
pubmed: 26031708
pmcid: 4657556
Flores LT, Bennett AV, Law EB, Hajj C, Griffith MP, Goodman KA. Patient-reported outcomes vs. clinican symptom reporting during chemoradiation for rectal cancer. Gastrointest Cancer Res. 2012;5:119–24.
pubmed: 23077685
pmcid: 3433260
Basch E, Jia X, Heller G, Barz A, Sit L, Fruscione M, et al. Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. J Natl Cancer Inst. 2009;101:1624–32.
pubmed: 19920223
pmcid: 2786917
Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;374:1621–34.
pubmed: 27119237
Lee SJ, Richardson PG, Sonneveld P, Schuster MW, Irwin D, San Miguel JF, et al. Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study. Br J Haematol. 2008;143:511–9.
pubmed: 18986387
Leleu X, Masszi T, Bahlis NJ, Viterbo L, Baker B, Gimsing P et al. Patient-reported health-related quality of life from the phase III TOURMALINE-MM1 study of ixazomib-lenalidomide-dexamethasone versus placebo-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma. Am J Hematol. 2018;93:981–3.
Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Špička I, Oriol A, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372:142–52.
pubmed: 25482145
Siegel DS, Dimopoulos MA, Ludwig H, Facon T, Goldschmidt H, Jakubowiak A, et al. Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. J Clin Oncol. 2018;36:728–34.
pubmed: 29341834
Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hájek R, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016;17:27–38.
pubmed: 26671818
Dimopoulos MA, Goldschmidt H, Niesvizky R, Joshua D, Chng WJ, Oriol A, et al. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol. 2017;18:1327–37.
pubmed: 28843768
Ludwig H, Moreau P, Dimopoulos MA, Mateos M-V, Kaiser MF, Hajek R, et al. Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma. Blood Cancer J. 2019;9:23.
pubmed: 30796199
pmcid: 6386751